Cox A, Der C
Genes Dev. 2024; 39(1-2):132-162.
PMID: 39638567
PMC: 11789494.
DOI: 10.1101/gad.352081.124.
Igarashi T, Yano K, Endo S, Shiotani B
Cancers (Basel). 2024; 16(20).
PMID: 39456601
PMC: 11506635.
DOI: 10.3390/cancers16203507.
Kudelka M, Lavin Y, Sun S, Fuchs E
Genes Dev. 2024; 39(1-2):18-35.
PMID: 39455281
PMC: 11789493.
DOI: 10.1101/gad.351990.124.
Tajiknia V, Pinho-Schwermann M, Srinivasan P, Hernandez Borrero L, Zhang L, Huntington K
Am J Cancer Res. 2024; 14(9):4523-4536.
PMID: 39417197
PMC: 11477830.
DOI: 10.62347/DVXL1377.
Casacuberta-Serra S, Gonzalez-Larreategui I, Capitan-Leo D, Soucek L
Signal Transduct Target Ther. 2024; 9(1):205.
PMID: 39164274
PMC: 11336233.
DOI: 10.1038/s41392-024-01907-z.
Tumor-Agnostic Therapy-The Final Step Forward in the Cure for Human Neoplasms?.
El-Sayed M, Bianco J, Li Y, Fabian Z
Cells. 2024; 13(12.
PMID: 38920700
PMC: 11201516.
DOI: 10.3390/cells13121071.
Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment.
Long S, Amparo A, Goodhart G, Ahmad S, Waters A
Front Oncol. 2024; 14:1402128.
PMID: 38800401
PMC: 11116577.
DOI: 10.3389/fonc.2024.1402128.
Interactions between Ras and Rap signaling pathways during neurodevelopment in health and disease.
Cherra 3rd S, Lamb R
Front Mol Neurosci. 2024; 17:1352731.
PMID: 38463630
PMC: 10920261.
DOI: 10.3389/fnmol.2024.1352731.
A New Dawn for Targeted Cancer Therapy: Small Molecule Covalent Binding Inhibitor Targeting K-Ras (G12C).
Li N, Liu C, Zhang W, Rao G
Curr Med Chem. 2023; 32(4):647-677.
PMID: 37936461
DOI: 10.2174/0109298673258913231019113814.
Modeling specific aneuploidies: from karyotype manipulations to biological insights.
Truong M, Cane-Gasull P, Lens S
Chromosome Res. 2023; 31(3):25.
PMID: 37640903
PMC: 10462580.
DOI: 10.1007/s10577-023-09735-7.
DNA methylation profiling in Trisomy 21 females with and without breast cancer.
Bejaoui Y, Alresheq S, Durand S, Vilaire-Meunier M, Maillebouis L, Al Haj Zen A
Front Oncol. 2023; 13:1203483.
PMID: 37538118
PMC: 10395079.
DOI: 10.3389/fonc.2023.1203483.
BLM promotes malignancy in PCa by inducing KRAS expression and RhoA suppression via its interaction with HDGF and activation of MAPK/ERK pathway.
Guo Y, Xu H, Huang M, Ruan Y
J Cell Commun Signal. 2022; 17(3):757-772.
PMID: 36574142
PMC: 10409945.
DOI: 10.1007/s12079-022-00717-8.
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors.
Lee J, Sivakumar S, Schrock A, Madison R, Fabrizio D, Gjoerup O
NPJ Precis Oncol. 2022; 6(1):91.
PMID: 36494601
PMC: 9734185.
DOI: 10.1038/s41698-022-00334-z.
Inhibition of colon cancer K-Ras mutation reduces cancer cell proliferation but promotes stemness and inflammation RAS/ERK pathway.
Qi Y, Zou H, Zhao X, Kapeleris J, Monteiro M, Li F
Front Pharmacol. 2022; 13:996053.
PMID: 36386200
PMC: 9650442.
DOI: 10.3389/fphar.2022.996053.
Immune Checkpoint Inhibitors and RAS-ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma.
Morante M, Pandiella A, Crespo P, Herrero A
Biomolecules. 2022; 12(11).
PMID: 36358912
PMC: 9687808.
DOI: 10.3390/biom12111562.
Drugging KRAS: current perspectives and state-of-art review.
Parikh K, Banna G, Liu S, Friedlaender A, Desai A, Subbiah V
J Hematol Oncol. 2022; 15(1):152.
PMID: 36284306
PMC: 9597994.
DOI: 10.1186/s13045-022-01375-4.
Pathological MAPK activation-mediated lymphatic basement membrane disruption causes lymphangiectasia that is treatable with ravoxertinib.
Janardhan H, Dresser K, Hutchinson L, Trivedi C
JCI Insight. 2022; 7(17).
PMID: 36073544
PMC: 9536262.
DOI: 10.1172/jci.insight.153033.
Functional and biological heterogeneity of KRAS mutations.
Huynh M, Hobbs G, Schaefer A, Pierobon M, Carey L, Diehl J
Sci Signal. 2022; 15(746):eabn2694.
PMID: 35944066
PMC: 9534304.
DOI: 10.1126/scisignal.abn2694.
Modeling receptor flexibility in the structure-based design of KRAS inhibitors.
Zhu K, Li C, Wu K, Mohr C, Li X, Lanman B
J Comput Aided Mol Des. 2022; 36(8):591-604.
PMID: 35930206
PMC: 9512760.
DOI: 10.1007/s10822-022-00467-0.
Understanding and drugging RAS: 40 years to break the tip of the iceberg.
Brady D, Hmeljak J, Dar A
Dis Model Mech. 2022; 15(2).
PMID: 35244677
PMC: 8905715.
DOI: 10.1242/dmm.049519.